Regentis Biomaterials, a regenerative medicine company dedicated to developing innovative tissue repair solutions, agreed to go public via a SPAC merger with OceanTech Acquisitions I, a special purpose acquisition company, in a $95m deal. “We are glad to have accomplished this major milestone to becoming a public company. Following the closing of the transaction, Regentis believes it will have greater access to the public capital markets and be able to get back to and accelerate the completion of its pivotal clinical study for GelrinC. GelrinC , at its midpoint of a pivotal study for the repair of cartilage injuries of the knee, shows great promise to provide patients with an effective and enduring therapeutic solution to this medical need, which is highly unsatisfied," Ehud Geller, Regentis Executive Chairman.